Amneal Pharmaceuticals (AMRX) EBIAT (2017 - 2025)
Historic EBIAT for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $18.1 million.
- Amneal Pharmaceuticals' EBIAT rose 5422.3% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.3 million, marking a year-over-year increase of 15771.37%. This contributed to the annual value of -$73.9 million for FY2024, which is 5162.76% down from last year.
- Amneal Pharmaceuticals' EBIAT amounted to $18.1 million in Q3 2025, which was up 5422.3% from $35.6 million recorded in Q2 2025.
- In the past 5 years, Amneal Pharmaceuticals' EBIAT ranged from a high of $35.6 million in Q2 2025 and a low of -$242.1 million during Q2 2022
- Over the past 5 years, Amneal Pharmaceuticals' median EBIAT value was $11.8 million (recorded in 2024), while the average stood at -$13.6 million.
- Over the last 5 years, Amneal Pharmaceuticals' EBIAT had its largest YoY gain of 42881.91% in 2023, and its largest YoY loss of 257662.51% in 2023.
- Over the past 5 years, Amneal Pharmaceuticals' EBIAT (Quarter) stood at -$20.5 million in 2021, then soared by 118.42% to $3.8 million in 2022, then crashed by 2576.63% to -$93.3 million in 2023, then skyrocketed by 112.78% to $11.9 million in 2024, then soared by 52.0% to $18.1 million in 2025.
- Its EBIAT was $18.1 million in Q3 2025, compared to $35.6 million in Q2 2025 and $24.6 million in Q1 2025.